logo
  •   Home
  • Applications
    • Indications
  • Business
  • EpiSwitch®
  • Products
    • EpiSwitch® Checkpoint Inhibitor Response Test
    • EpiSwitch® COVID-19 Severity Test
    • EpiSwitch® Explorer Array Kit
    • EPISWITCH® ANALYTICAL PORTAL
    • EpiSwitch® Service
  • Investors
    • Investors Overview
    • Results and Presentations
    • Share Price Information
    • Regulatory News
    • Board & Governance
    • Key Corporate Documents
    • AIM Rule 26
    • Email Alerts
    • Investor Contacts
  • News
  • About Us
    • History
    • Board of Directors
    • Management Team
    • Scientific Advisory Panel
    • Values
    • Careers
    • Contact Us

Oxford BioDynamics’ EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

November 8, 2019
|In Events
|By oxfordbiodynamics

Journal articles P142

Journal articles P143

Press Release

Links to top articles –

Chase

Seeking Alpha

MarketWatch

MorningStar

PR Newswire

Associated Press

Finanzen.net

Yahoo! Finance

Daily Herald

Buffalo News

 

  • Prev
  • Next

Terms of Use / Site Map / Privacy Policy / Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571
© 2002-2021 Oxford Biodynamics Plc

Privacy Preference Center

Privacy Preferences